- Report
- February 2026
- 365 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Clinical Trials
- April 2025
- 120 Pages
Global
From €2627EUR$3,000USD£2,280GBP
- Report
- September 2025
- 149 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- January 2026
- 187 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1314EUR$1,500USD£1,140GBP
- Report
- December 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- November 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- September 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- May 2025
- 472 Pages
Global
From €6126EUR$6,995USD£5,317GBP
- Report
- February 2026
- 262 Pages
Global
From €6126EUR$6,995USD£5,317GBP
- Report
- February 2026
- 388 Pages
Global
From €6126EUR$6,995USD£5,317GBP
- Report
- December 2025
- 391 Pages
Global
From €4203EUR$4,799USD£3,648GBP
- Report
- January 2026
- 193 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 183 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 192 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 191 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 192 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 194 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 191 Pages
Global
From €3450EUR$3,939USD£2,994GBP

The Natural Killer Cell market within the context of Oncology Drugs is a rapidly growing field of research and development. Natural Killer Cells (NK Cells) are a type of white blood cell that play an important role in the body's immune system. They are capable of recognizing and destroying cancer cells, as well as other abnormal cells. NK Cells have been used in the treatment of various types of cancer, including leukemia, lymphoma, and multiple myeloma. NK Cells have also been used in combination with other treatments, such as chemotherapy and radiation therapy, to improve the efficacy of these treatments.
In recent years, the development of NK Cell-based therapies has been a major focus of research and development in the oncology drug market. Several companies have developed NK Cell-based therapies, including CAR-T therapies, which are designed to target and destroy cancer cells. These therapies have shown promising results in clinical trials and are being evaluated for their potential to treat a variety of cancers.
Companies in the Natural Killer Cell market within the context of Oncology Drugs include Kite Pharma, Juno Therapeutics, Novartis, and Celgene. Show Less Read more